Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: An analysis of 15,780 patients from the INTERHEART study

Diabetologia

Volumn 53, Issue 12, 2010, Pages 2509-2517

  Gerstein, H C ^a,b   Islam, S ^a,b   Anand, S ^a,b   Almahmeed, W ^c   Damasceno, A ^d   Dans, A ^e   Lang, C C ^f   Luna, M A ^g   McQueen, M ^a,b   Rangarajan, S ^a,b   Rosengren, A ^h   Wang, X ⁱ   Yusuf, S ^a,b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^d EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^e UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g UNIVERSITY OF VIRGINIA   (United States)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ Beijing Hypertension League Institute   (China)

Author keywords

Case control; Diabetes; Dysglycaemia; Glycated haemoglobin; Myocardial infarction

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HEMOGLOBIN A1C;

ABDOMINAL OBESITY; ACUTE HEART INFARCTION; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; ETHNIC DIFFERENCE; FEMALE; FOOD INTAKE; FRUIT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SEX DIFFERENCE; VEGETABLE;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ETHNIC GROUPS; FEMALE; GLUCOSE METABOLISM DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PREVALENCE; RISK FACTORS;

EID: 78649335498     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1871-0     Document Type: Article

References (24)

1. International Diabetes Federation (2008) Prevalence Estimates of Diabetes 2007. Diabetes Atlas, 3rd edn. IDF, Brussels
2. LL Lipscombe JE Hux 2007 Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study Lancet 369 750 756 10.1016/S0140-6736(07)60361-4 17336651 (Pubitemid 46321630)
3. Centers for Disease Control and Prevention (YEAR) Prevalence of diagnosed diabetes by age, United States, 1980-2005. Available from http://www.cdc.gov/ diabetes/statistics/prev/national/figbyage.htm accessed 13 June 2008
4. CM Lawes V Parag DA Bennett, et al. 2004 Blood glucose and risk of cardiovascular disease in the Asia Pacific region Diab Care 27 2836 2842 1:STN:280:DC%2BD2cnhtlWhtQ%3D%3D 10.2337/diacare.27.12.2836 (Pubitemid 39565046)
5. C Held HC Gerstein S Yusuf, et al. 2007 Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk Circulation 115 1371 1375 1:CAS:528:DC%2BD2sXislaisbw%3D 10.1161/CIRCULATIONAHA.106.661405 17339550 (Pubitemid 46648372)
6. EJ Brunner MJ Shipley DR Witte JH Fuller MG Marmot 2006 Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study Diab Care 29 26 31 10.2337/diacare.29.01.06.dc05-1405
7. DECODE Study Group EDEG 2003 Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diab Care 26 688 696 10.2337/diacare.26.3.688 (Pubitemid 36929329)
8. KT Khaw N Wareham S Bingham R Luben A Welch N Day 2004 Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk Ann Intern Med 141 413 420 1:CAS:528:DC%2BD2cXos1Cjtrg%3D 15381514
9. E Selvin J Coresh SH Golden FL Brancati AR Folsom MW Steffes 2005 Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study Arch Intern Med 165 1910 1916 10.1001/archinte.165.16.1910 16157837 (Pubitemid 41352087)
10. HC Gerstein K Swedberg J Carlsson, et al. 2008 The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Arch Intern Med 168 1699 1704 1:CAS:528:DC%2BD1cXhtVGhurzP 10.1001/archinte.168.15.1699 18695086
11. M Bartnik L Ryden R Ferrari, et al. 2004 The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart Eur Heart J 25 1880 1890 1:CAS:528:DC%2BD2cXptFOgt7k%3D 10.1016/j.ehj.2004.07.027 15522466 (Pubitemid 39452604)
12. DY Hu CY Pan JM Yu 2006 The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey Eur Heart J 27 2573 2579 1:CAS:528:DC%2BD28XhtlanurnE 10.1093/eurheartj/ehl207 16984927 (Pubitemid 44627302)
13. S Yusuf S Hawken S Ounpuu, et al. 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937 952 10.1016/S0140-6736(04) 17018-9 15364185 (Pubitemid 39208455)
14. T Stevenson 1999 Glycosal: the first rapid, point-of-care test for the determination of hemoglobin A1c in patients with diabetes Diabetes Technol Ther 1 425 431 1:CAS:528:DC%2BD3cXhsF2mtLg%3D 10.1089/152091599316946 11474827
15. MJ McQueen S Hawken X Wang, et al. 2008 Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study Lancet 372 224 233 1:CAS:528: DC%2BD1cXoslWkt7w%3D 10.1016/S0140-6736(08)61076-4 18640459 (Pubitemid 351978112)
16. A Rosengren S Hawken S Ounpuu, et al. 2004 Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study Lancet 364 953 962 10.1016/S0140-6736(04)17019-0 15364186 (Pubitemid 39208456)
17. A Norhammar A Tenerz G Nilsson, et al. 2002 Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study Lancet 359 2140 2144 1:CAS:528: DC%2BD38XkslGhsb8%3D 10.1016/S0140-6736(02)09089-X 12090978 (Pubitemid 34694020)
18. E Selvin MW Steffes H Zhu, et al. 2010 Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults N Engl J Med 362 800 811 1:CAS:528:DC%2BC3cXivV2hu7Y%3D 10.1056/NEJMoa0908359 20200384
19. Origin Trial Investigators 2008 Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) Am Heart J 155 26 32
20. RM Califf M Boolell SM Haffner, et al. 2008 Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Am Heart J 156 623 632 10.1016/j.ahj.2008. 05.017 18946890
21. Diabetes Trials Unit, University of Oxford. Acarbose cardiovascular cvaluation. Available from www.dtu.ox.ac.uk/index.php?maindoc=/ace/overview.php, accessed 27 October 2008
22. KK Ray SR Seshasai S Wijesuriya, et al. 2009 Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 1765 1772 1:CAS:528:DC%2BD1MXmtleksbc%3D 10.1016/S0140-6736(09)60697-8 19465231
23. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N (2009) Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 19:604-612
24. HC Gerstein 2009 Is it possible to reduce cardiovascular risk with glucose-lowering approaches? Nat Rev Endocrinol 5 270 275 10.1038/nrendo.2009.49 19444260